• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Life Sciences | News, Analysis, Insights - HIT Consultant

Accenture: How New Science is Reshaping The Biopharma Landscape

by Fred Pennic 04/05/2019 Leave a Comment

Accenture: How New Science is Reshaping The Biopharma Landscape

Accenture has released new research that unveils strong evidence that the biopharma industry is facing compressive disruption when a series of innovations, macroeconomic factors, and other changes combine to squeeze profits over a decade or more.  However, it also unveils a powerful growth engine: an emerging category that Accenture calls 'New Science' that is expected to drive 54% of the biopharma industry’s growth through 2022. What is New Science? New Science is an evolving, unique
Read More

PAREXEL Unveils Patient Sensor Solution To Transform Clinical Trial Data Collection

by Fred Pennic 04/03/2017 Leave a Comment

PAREXEL Patient Sensor Solution

PAREXEL International Corporation (NASDAQ: PRXL), a biopharmaceutical services provider has unveiled its new patient sensor solution that securely captures, transmits, stores and visualizes study subject data in clinical trials. The new offering is powered by he Perceptive MyTrials® Analytics platform, enables an end-to-end services and technology solution that facilitates the remote collection of study subject data via medical devices.The PAREXEL® patient sensor solution supports the generation
Read More

Pharma Deals Vital to Offsetting $2.5B Drug Development Cost

by HITC Staff 12/15/2015 Leave a Comment

With the average cost of getting a novel drug to market at almost $2.5 billion, and few products achieving blockbuster status, deal-making is becoming increasingly vital for pharmaceutical companies to offset rising Research and Development (R&D) costs, says business intelligence provider GBI Research. The company’s latest CBR Pharma report* states that pharmaceutical companies are considering various strategies to overcome the current challenges, which also include shifts in patent laws
Read More

BioMaryland Center Awards $1.5M to Johns Hopkins and 7 Biotech Companies

by Jasmine Pennic 03/04/2014 Leave a Comment

BioMaryland Center Awards $1.5M to Johns Hopkins and 7 Biotech Companies

Governor Martin O’Malley announced today that the State, through the BioMaryland Center, has awarded nearly $1.5 million to seven innovative life sciences companies and one educational institution through its Biotechnology Development Awards program. The companies, which received up to $200,000 each, will use the funding to accelerate the commercialization of a wide range of treatments and technologies; including a device that detects concussions in youths engaged in sports; a tool that takes a
Read More

  • Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 96
  • Go to page 97
  • Go to page 98

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Doctors Don’t Buy Medical Tech Anymore. IT Does.

Best Practices for IT and Clinical Collaboration in Medical Tech Implementation

Most-Read

Microsoft Copilot Health, Integrates Apple Health, Oura, and 50,000 EHRs in New AI Push

Microsoft Launches Copilot Health, Integrates Apple Health, Oura, and 50,000 EHRs in New AI Push

Health Recovery Solutions (HRS) Acquires Rimidi for Chronic Care Management and RPM Integration

Health Recovery Solutions (HRS) Acquires Rimidi for Chronic Care Management and RPM Integration

RadNet Subsidiary DeepHealth Acquires French Radiology AI Leader Gleamer

RadNet’s $269M AI Play: DeepHealth Acquires French AI Gleamer

Walgreens Launches Virtual Weight Management Platform for Self-Pay GLP-1 Patients

Walgreens Launches Virtual Weight Management Platform for Self-Pay GLP-1 Patients

KLAS Digital Pathology 2026 Report: Top IMS, Scanner, and AI Vendors Evaluated

KLAS Digital Pathology 2026 Report: Top IMS, Scanner, and AI Vendors Evaluated

The "Platform" Squeeze: Epic Releases Native AI Charting, Putting Venture-Backed Scribes on Notice

The “Platform” Squeeze: Epic Releases Native AI Charting, Putting Venture-Backed Scribes on Notice

Analysis: Oracle Cerner’s Plans for a National EHR

Oracle May Cut 30k Jobs and Sell Cerner to Fund $156B OpenAI Deal

The $1.9B Exit: Why CommonSpirit is Insourcing Revenue Cycle and Tenet is Betting Big on Conifer AI

The $1.9B Exit: Why CommonSpirit is Insourcing Revenue Cycle and Tenet is Betting Big on Conifer AI

KLAS 2026 Rankings: Aledade and Guidehealth Named Top VBC Enablement Firms

KLAS 2026 Rankings: Aledade and Guidehealth Named Top VBC Enablement Firms

Beyond the Hype: New KLAS Data Validates the Financial and Clinical ROI of Ambient AI

Beyond the Hype: New KLAS Data Validates the Financial and Clinical ROI of Ambient AI

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |